logo
Florida Tech withdraws from Cape Canaveral rocket-noise study, citing its narrow scope

Florida Tech withdraws from Cape Canaveral rocket-noise study, citing its narrow scope

Yahoo21-07-2025
Citing insufficient pricing and scope of research, the Florida Institute of Technology has withdrawn from a partnership with the city of Cape Canaveral to monitor potential impacts of rocket launches on buildings and infrastructure.
This $10,019 study, which the Cape Canaveral City Council approved in April, called for Florida Tech to install sensors — including sound level meters, accelerometers and air quality monitors — at a handful of buildings across Cape Canaveral and collect data before, during and after rocket launches.
But upon further review, Florida Tech withdrew because "the $10,000 cost and narrow purview are insufficient to appropriately examine the issues at hand," university spokesperson Wes Sumner said.
Specifically, Sumer said a more robust study using more sensors in more locations — including weather sensors — would better address the complexities at play.
Cape Canaveral: Is there a launch today? Upcoming SpaceX, NASA, ULA rocket launch schedule at Cape Canaveral
"Florida Tech initially estimates that cost for an appropriately detailed study could be $100,000 or more. The ongoing work from faculty at (Brigham Young University) into the acoustics of rockets, for example, which has produced multiple journal articles, alludes to the broader effort needed for more meaningful, impactful data," Sumner said in an email.
Why study rocket launch acoustics? In a news post, City Hall staffers said Cape Canaveral residents are concerned about the possibility of long-term structural damages such as cracking, foundation settling and shattered windows — particularly in light of increasing launch rates and rocket sizes. Florida's Space Coast remains on track to crack the 100-launch barrier for this first time this year.
"The City's goal in pursuing this research was to determine the long-term impacts on the built environment of repeated rocket launches with ever more powerful launch vehicles, and we still wish to accomplish this," Zachary Eichholz, chief resilience manager for the city of Cape Canaveral, said in an email.
"It is currently exploring alternative means to conduct this research, including future initiatives with FIT and other research teams at other universities," Eichholz said.
Last week, U.S. Air Force officials collected environmental comments during public hearings in Titusville, Cape Canaveral and Cocoa about SpaceX's proposal to start launching up to 76 Starship-Super Heavy rocket systems per year — with up to 152 sonic-boom-producing landings — at Cape Canaveral Space Force Station.
Those Starship-Super Heavy future liftoffs from Launch Complex 37 would occur 9 miles from Cape Canaveral's closest condominium and 10.4 miles from City Hall, Eichholz said. SpaceX did not respond to messages seeking comment for this story.
Space Force, SpaceX, NASA conducting bigger study in CA
In terms of scope, a far-larger research collaboration is tracking rocket sonic-boom data this year near Vandenberg Space Force Base in California. This study involves the Space Force, BYU, California State University-Bakersfield, SpaceX, NASA and the Federal Aviation Administration.
A network of about 25 monitoring stations is dispatched across 500 square miles of California's central coast, collecting data to create a three-dimensional sound map.
"It's like trying to catch lightning in a bottle," Kent Gee, who chairs BYU's Department of Physics and Astronomy, said in a Space Force press release. "All launches generate sonic booms; however, their audibility to the public is influenced by several factors, including the launch trajectory, the size of the rocket, and atmospheric conditions.'
Specifically, the California coastal region's multiple "microclimates" add to the complexities, and Gee said launches with nearly identical flight paths can produce vastly different noise levels on the ground. The press release said this variability "has sent researchers on a quest to unravel the complex interplay between rocket trajectories, weather conditions, and topography."
Air Force shares Starship-Super Heavy sound details
An Air Force 176-page draft environmental impact statement said Starship-Super Heavy noise would represent "a community annoyance" for residential neighborhoods in Cocoa Beach, Cape Canaveral, Titusville and Merritt Island — particularly during Super Heavy booster landings.
During last week's public hearings, mention was made of SpaceX's proposed actions to reduce noise impacts using sound suppression technology:
A water deluge system would spray large volumes of water onto the launch pad during liftoff, absorbing acoustic energy and converting it to steam — significantly reducing sound intensity.
Flame trenches beneath the launch pad would redirect and disperse exhaust and sound energy away from sensitive areas.
In addition, SpaceX will coordinate with Space Launch Delta 45 to alert the public in advance of launches and potential sonic booms via websites and social media.
If a sonic boom causes suspected property damage, Air Force meeting materials said building owners could launch a formal claims process by contacting the Space Launch Delta 45 public affairs office. Compensation would be provided in accordance with FAA regulations, the Commercial Space Launch Act and other relevant law and policy.
For the latest news from Cape Canaveral Space Force Station and NASA's Kennedy Space Center, visit floridatoday.com/space. Another easy way: Click here to sign up for our weekly Space newsletter.
Rick Neale is a Space Reporter at FLORIDA TODAY. Contact Neale at Rneale@floridatoday.com. Twitter/X: @RickNeale1
Space is important to us and that's why we're working to bring you top coverage of the industry and Florida launches. Journalism like this takes time and resources. Please support it with a subscription here.
This article originally appeared on Florida Today: Florida Tech withdraws from rocket-noise study with city of Cape Canaveral
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

Yahoo

time23 minutes ago

  • Yahoo

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

Yahoo

time42 minutes ago

  • Yahoo

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

Yahoo

time3 hours ago

  • Yahoo

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store